Zentalis Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Zentalis Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q2 2024.
  • Zentalis Pharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 24.2 %, a 5.13% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 24.2 +1.18 +5.13% Jun 30, 2024
Q1 2024 21.8 -1.68 -7.15% Mar 31, 2024
Q4 2023 23 -0.71 -3% Dec 31, 2023
Q3 2023 22.5 -1.24 -5.22% Sep 30, 2023
Q2 2023 23 +2.55 +12.5% Jun 30, 2023
Q1 2023 23.5 +3.65 +18.4% Mar 31, 2023
Q4 2022 23.7 +7.42 +45.6% Dec 31, 2022
Q3 2022 23.8 +11.6 +95.2% Sep 30, 2022
Q2 2022 20.5 Jun 30, 2022
Q1 2022 19.9 Mar 31, 2022
Q4 2021 16.3 Dec 31, 2021
Q3 2021 12.2 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.